Knowledge Hub

Global Clostridium Diagnostics Market to Exhibit 15% CAGR from 2017 to 2021

Press Release   •   Aug 16, 2017 05:17 EDT

A detailed market research report recently added to the vast research report portfolio of covers the detailed overview of the global market for clostridium diagnostics. The report, titled "Global Clostridium Diagnostics Market 2017-2021," states that the global clostridium diagnostics market will exhibit a promising CAGR of close to 15% from 2107 to 2021. Factors such as the rising prevalence of clostridium-related diseases, the alarming rise in the number of such conditions, and the rising population of geriatrics will stimulate market growth through the report's forecast period.

The report segments the global clostridium diagnostics market on the basis of technology into immunoassays and molecular diagnostics. Of these, the segment of immunoassays contributed the dominant share of revenue to the overall market owing to the high prevalence of a variety of chronic diseases across the globe and the high usage of immunoassays in the field of oncology. Immunoassays will continue to witness a massive rise in usage through the forecast period owing to the cost effectiveness of the diagnostic method, rapid technological advancements, and time efficient diagnosis.
On the basis of the key end-users of the clostridium diagnostics market, the report segments the market into independent laboratories, hospitals, and physicians' clinics. Of these, the segment of hospitals is the presently most preferred mode of undergoing clostridium diagnostics tests. The preference to hospitals over other common varieties of medical healthcare centers is rising owing to the availability of various kinds of tests in hospitals, including invasive and non-invasive varieties. Preference to hospitals is also expected to continue to remain high over the report's forecast period as most hospitals have well-equipped diagnostics labs with advanced diagnostics technologies.
Get Sample Copy Of This Report @
From a geographical standpoint, the report covers the market for clostridium diagnostics in regions such as Americas, Asia Pacific (APAC), and Europe, Middle East, and Africa (EMEA). Of these, the market for clostridium diagnostics in Americas will be driven by the presence of well-established laboratory systems and several awareness programs to educate the masses regarding the benefits of early diagnosis. Moreover, the rising awareness regarding presymptomatic blood screening for genetic and infectious diseases will also drive the market in the region throughout the forecast period.
View Press Release @
The report states that the global clostridium diagnostics market features the presence of a large number of companies, presenting a largely fragmented vendor landscape with a high level of competition. Companies compete with their peers on the basis of factors such as product cost, differentiation, technological developments, and the adoption of innovative technologies for product development.
Some of the leading companies operating in the market are Beckman Coulter, Siemens Healthineers, Abbott, F. Hoffmann-La Roche, Olympus, Diazyme Laboratories, Chrono-log Corporation, FUJIREBIO DIAGNOSTICS, bioMerieux, Sysmex Corporation, Corgenix, Thermo Fisher Scientific, QIAGEN, and Hologic.